sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
IgAÉö²¡¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > IgAÉö²¡¶¯ÎïÄ£×Ó

ǰÑÔ

ÉöСÇò¼²²¡(glomerular diseases)ÊDz¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏÖ¡¢²¡Àí¸Ä±ä¡¢²¡³ÌºÍÔ¤ºó²»¾¡ÏàͬµÄÖ÷ÒªÀÛ¼°Ë«ÉöÉöСÇòµÄÒ»×é¼²²¡£¬¿É·ÖΪԭ·¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔ¡£´ó¶¼ÉöСÇòÉöÑ×ÊÇÃâÒ߽鵼ÐÔÑ×Ö¢¼²²¡¡£Ò»Ñùƽ³£ÒÔΪ£¬ÃâÒß»úÖÆÊÇÉöСÇò²¡µÄʼ·¢»úÖÆ£¬ÉöСÇò¼²²¡¶¯ÎïÄ£×ÓÔÚ̽ÌÖ·¢²¡»úÖÆ¡¢²¡ÀíÀú³ÌÒÔ¼°ÁÙ´²ÖÎÁƵȷ½ÃæÊ©Õ¹Ö÷Òª×÷Óᣱ¾½ÚÖ÷ÒªÏÈÈÝÁËϵĤÔöÖ³ÐÔÉöСÇòÉöÑס¢Thy1ϵĤÔöÉúÐÔÉöÑס¢Ï¸Ð¡²¡±äÐÍÉö²¡¡¢IgAÉö²¡ÒÔ¼°ÉöСÇòÓ²»¯ÐÔÉö²¡¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁìºÍÌØµã¡£

lgAÉö²¡(IgA nephropathy)ÊÇ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡£¬ÆäÌØµãΪÉö»î¼ìÃâÒß²¡Àíѧ¼ì²éÔÚÉöСÇòÏµÄ¤ÇøÒÔIgAΪÖ÷µÄÃâÒ߸´ºÏÎï³Á»ý£¬Í¬Ê±±£´æÏµÄ¤Ï¸°ûÔöÉú£¬»ùÖÊÔö¶à¡£IgAÉö²¡µÄ·¢²¡»úÖÆÉÐδÍêÈ«ÇåÎú£¬Îª´ËÈËÃǽ¨ÉèÁËÐí¶àlgAÉö²¡¶¯ÎïÄ£×Ó£¬ÓÃÀ´Õ¹ÏÖlgAÉö²¡µÄ·¢²¡»úÖÆ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

BSA¡¢Ö¬¶àÌÇ(lipopolysaccharides,LPS)ºÍCCI4ÍŽáÓ¦ÓÃÄܹ»Ôì³É賦µÀð¤Ä¤ÃâÒß¹¦Ð§ÔÓÂÒ£¬ÒýÆð»úÌå¶ÔѪҺºÍÉöСÇòÖеĹýÁ¿lgAɨ³ýÕϰ­£¬µ¼ÖÂÉöСÇòÏµÄ¤ÇøÒÔIgAΪÖ÷µÄÃâÒ߸´ºÏÎï³Á»ý£¬ÒÔ¼°ÏµÄ¤Ï¸°ûÔöÉú¡¢»ùÖÊÔö¶àµÈ²¡Àí¸Ä±ä£¬×îÖÕ·ºÆðÄòÂѰ׺ÍÄòѪµÈlgAÉö²¡µÄµä·¶Ö¢×´¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ʵÑéÀú³Ì ÐÛÐÔSprague Dawley´óÊó£¨ÌåÖØ220~260g)¿Ú·þÃâÒßÔ­BSA (400mg/kg)£¬¸ôÌì¹à裬һÁ¬6ÖÜ £»Æ¤ÏÂ×¢Éä±ÍÂéÓÍ(0.5ml)ºÍCCl4(0.1ml),1´Î£¯ÖÜ£¬Ò»Á¬9Öܲ¢ÍŽáÔËÓÃLPS£¨»®·ÖÓÚµÚ6¡¢8 ÖÜÒÔ0.05mgβ¾²Âö×¢É䣩¡£µÚ10ÖÜÄ©Õý·¨¶¯ÎȡѪ±ê±¾ºÍÉöÔà×öÏìÓ¦¼ì²é¡£

2.Ö¸±ê¼ì²â ²â¶¨ÑªÇåÇåÂѰס¢ÑªÇå×ÜÂѰס¢BUN¡¢Cr¡¢¹È±ûת°±Ã¸ºÍ¹È²Ýת°±Ã¸¡£ÁíÍ⣬ÿ¸ôÈýÖܼì²â1´Î24СʱÄòÂѰ׺ÍÄòͨÀý¡£ÉöÔಡÀíÇÐÆ¬¾ÙÐÐH&EºÍPASȾɫ£¬¼ÆÊýÉöСÇò¸öÊý²¢ÅÌËãÉöСÇòÏµÄ¤ÇøÕ¼Õû¸öÉöÔàëϸѪ¹Ü´ÔÃæ»ýµÄ°Ù·Ö±È£¬×îºó£¬¶ÔÉöÔà¾ÙÐÐIgAÃâÒßÓ«¹âÇ¿¶È·Ö¼¶¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.´óÊó¾ù·ºÆðÂѰ×Äò£¬ÆäÖÐ70£¥·ºÆðÈâÑÛѪÄò£¬30£¥·ºÆð¾µÏÂѪÄò£¬ÃâÒßÓ«ÏÊÃ÷ʾÉö×éÖ¯£®IgA Ç¿¶È(2Æß3+£©£¬¹â¾µPASȾɫÏÔʾÓÐÃÖÂþÐÔµÄÇáÖжÈÏµÄ¤ÇøÔöÉú£¬ÑªÇåÂѰ׽µµÍ£¬µ«×ª°±Ã¸Ë®Æ½ÎÞת±ä¡£ 2.ÔÚÔìÄ£ÒªÁìÖУ¬LPSÊÇÃâÒß×ô¼Á£¬¶¾ÐÔ½ÏÍâ

2.¶¾ËØÆÏÌÑÇò¾ú³¦¶¾ËØÈõ£¬²»Ò×¶Ô¶¯Îï»úÌåÔì³ÉË𺦡£½«¿Ú·þÃâÒßÔ­BSAµÄ¼ÁÁ¿Îª400mg/kg£¬¸ôÈÕ1´ÎÒÔ¼°CC14ÒÔ0.1ml¼Á×îÆ¤ÏÂ×¢É価¿ÉÄÜïÔÌ­¶Ô¸ÎÔàµÄË𺦡£Í¨¹ýÒÔÉϸÄÁ¼£¬Ä£×Ó×élgAÔÚÉöÔà×éÖ¯ÓнÏÇ¿³Á»ý£¬²Ù×÷ÆðÀ´¸üÀû±ãºÍÇå¾²£¬²»Ò×ÒýÆð¸¹Ç»Ñ¬È¾ºÍ¶¯ÎïéæÃü£¬²¢ÇÒÎÞÏÔןÎÔàË𺦡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

lgAÉö²¡ÊÇ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡£¬Ô¼Õ¼Ô­·¢ÐÔÉöСÇò¼²²¡µÄ1/3¡£½ÓÄɸ´ºÏ¸ÄÁ¼·¨ÔìÄ£ÊÇÏÖÔÚlgAÉö²¡ÖнÏΪ¿É¿¿Îȹ̡¢ÀÖ³ÉÂʸߣ¬ÇÒ²¡Àí¡¢ÁÙ´²Ö¸±ê¿¿½üÈËÀàIgAÉö²¡µÄ¶¯ÎïÄ£×Ó¡£ËüսʤÁ˿ڷþÃâÒßÔ´£«¸ÎÔàÇгý£«ÃâÒß×ô¼Á¸´ºÏÔìÄ£·¨¶¯ÎïéæÃüÂʸߣ¨Ô¼50%£©µÄÈõµã £»ÆÏÌÑÇò¾ú³¦¶¾ËØ£«¿Ú·þÃâÒßÔ´£«ÃâÒß×ô¼Á¸´ ºÏÔìÄ£·¨ÒòÆÏÌÑÇò¾ú³¦¶¾ËØÊÇÍâ¶¾ËØ£¬¶¾ÐÔ´ó£¬Ò×ÒýÆð»úÌåË𺦠£»¸¹Ç»×¢ÉäCC14Òý·¢µÄIgAÉö²¡Ä£ ÐÍ£¬ËäÈ»ÓиßÇ¿¶ÈµÄIgA³Á»ý£¬µ«¸ÎÔ๦ЧËðº¦ÑÏÖØ£¬³£°éÓиÎϸ°û»µËÀ¡¢±äÐԺͼÙСҶÌìÉú¡£ÓÿгÝÀදÎï¸´ÖÆµÄIgAÉö²¡Ä£×Ó£¬ÆäѪÇåIgAÌØÕ÷ÓëÈËÀà±£´æ½Ï´ó²î±ð£¬¹ÊÆÚÍû½¨Éè»ùÒò¹¤³ÌÄ£×ÓÀ´Õ½Ê¤Æäȱ·¦¡£

  

²Î¿¼ÎÄÏ×£º

1.ÌÀÓ±£¬Â¦Ì½Ææ£¬³É²ÊÁª£¬µÈʵÑéÐÔIgAÉö²¡Ä£×ÓµÄˢУ®ÖÐɽ´óѧѧ±¨£¨Ò½Ñ§¿ÆÑ§°æ£©£¬2006,27 (2): 184-187

2.Î⺺Àû£¬Ëïΰ£®°¢Èá±ÈÐǽ¨ÉèÉö²¡Ä£×ӵįÀ¼Û£®ÖйúÖÐÒ½¼±Ö¢£¬2010,19 (2):290-191

3.ÕÅÀö·Ò£¬»ÆÎÄÕþ£¬ÖìС馣¬µÈ£®°¢Ã¹ËØÉö²¡ÉöСÇòÓ²»¯¶¯ÎïÄ£×ÓµÄÑо¿. ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2005,6 (4):195-199

4.Õſ˷Ç£¬ÕÅÁÁ£¬ÎâÐÛ·É£¬µÈ£®´óÊó¿¹Thy1ϵĤÔöÉúÐÔÉöСÇòÉöÑ×Ä£×Ó·¢²¡»úÖÆÌ½ÌÖ£®ËÄ´¨´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬ 2004,35 (2): 188-190

5.³Â¹ãƽ£¬¹ù¹§ÒÀ£¬ÕÅԶ𣬵ȣ®´óÊóThy1¿¹ÑªÇåÖÆ±¸¼°ÏµÄ¤ÔöÉúÐÔÉöÑ×Ä£×ӵĽ¨É裮ÁÙ´²ÓëʵÑ鲡ÀíѧÔÓÖ¾£¬1996, 12 (3):241-243

6.»ÆÊ¤£¬ËïÁÖ£¬Ò¶Èθߣ¬µÈ£®Á½ÖÖϵĤÔöÖ³ÐÔÉöÑ×´óÊóÄ£×ӵĽ¨Éè½ÏÁ¿£®ÖйúʵÑ鶯Îïѧ±¨£¬2002, 10 (4): 236-238

7.Marquina R, Dfez MA,López-Hoyos M,el al. Inhibition of B cell death causes the development of an lgA nephropathy in(New Zealand white x C578L/6)F(l)-bel-2 transgenic mice. J lmmunol,2004,172(11):7177-7185

8.Zhang Z, Kundu GC, Yuan CJ, el al. Severe fibroneclin­deposit renal glomerular disease in mice lacking uteroglobin. Science, 1997,276(5317): 1408-1412

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > IgAÉö²¡¶¯ÎïÄ£×Ó
IgAÉö²¡¶¯ÎïÄ£×Ó

ǰÑÔ

ÉöСÇò¼²²¡(glomerular diseases)ÊDz¡Òò¡¢·¢²¡»úÖÆ¡¢ÁÙ´²ÌåÏÖ¡¢²¡Àí¸Ä±ä¡¢²¡³ÌºÍÔ¤ºó²»¾¡ÏàͬµÄÖ÷ÒªÀÛ¼°Ë«ÉöÉöСÇòµÄÒ»×é¼²²¡£¬¿É·ÖΪԭ·¢ÐÔ¡¢¼Ì·¢ÐÔºÍÒÅ´«ÐÔ¡£´ó¶¼ÉöСÇòÉöÑ×ÊÇÃâÒ߽鵼ÐÔÑ×Ö¢¼²²¡¡£Ò»Ñùƽ³£ÒÔΪ£¬ÃâÒß»úÖÆÊÇÉöСÇò²¡µÄʼ·¢»úÖÆ£¬ÉöСÇò¼²²¡¶¯ÎïÄ£×ÓÔÚ̽ÌÖ·¢²¡»úÖÆ¡¢²¡ÀíÀú³ÌÒÔ¼°ÁÙ´²ÖÎÁƵȷ½ÃæÊ©Õ¹Ö÷Òª×÷Óᣱ¾½ÚÖ÷ÒªÏÈÈÝÁËϵĤÔöÖ³ÐÔÉöСÇòÉöÑס¢Thy1ϵĤÔöÉúÐÔÉöÑס¢Ï¸Ð¡²¡±äÐÍÉö²¡¡¢IgAÉö²¡ÒÔ¼°ÉöСÇòÓ²»¯ÐÔÉö²¡¶¯ÎïÄ£×ӵĽ¨ÉèÒªÁìºÍÌØµã¡£

lgAÉö²¡(IgA nephropathy)ÊÇ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡£¬ÆäÌØµãΪÉö»î¼ìÃâÒß²¡Àíѧ¼ì²éÔÚÉöСÇòÏµÄ¤ÇøÒÔIgAΪÖ÷µÄÃâÒ߸´ºÏÎï³Á»ý£¬Í¬Ê±±£´æÏµÄ¤Ï¸°ûÔöÉú£¬»ùÖÊÔö¶à¡£IgAÉö²¡µÄ·¢²¡»úÖÆÉÐδÍêÈ«ÇåÎú£¬Îª´ËÈËÃǽ¨ÉèÁËÐí¶àlgAÉö²¡¶¯ÎïÄ£×Ó£¬ÓÃÀ´Õ¹ÏÖlgAÉö²¡µÄ·¢²¡»úÖÆ¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ £»úÖÆ¡¿£º

BSA¡¢Ö¬¶àÌÇ(lipopolysaccharides,LPS)ºÍCCI4ÍŽáÓ¦ÓÃÄܹ»Ôì³É賦µÀð¤Ä¤ÃâÒß¹¦Ð§ÔÓÂÒ£¬ÒýÆð»úÌå¶ÔѪҺºÍÉöСÇòÖеĹýÁ¿lgAɨ³ýÕϰ­£¬µ¼ÖÂÉöСÇòÏµÄ¤ÇøÒÔIgAΪÖ÷µÄÃâÒ߸´ºÏÎï³Á»ý£¬ÒÔ¼°ÏµÄ¤Ï¸°ûÔöÉú¡¢»ùÖÊÔö¶àµÈ²¡Àí¸Ä±ä£¬×îÖÕ·ºÆðÄòÂѰ׺ÍÄòѪµÈlgAÉö²¡µÄµä·¶Ö¢×´¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.ʵÑéÀú³Ì ÐÛÐÔSprague Dawley´óÊó£¨ÌåÖØ220~260g)¿Ú·þÃâÒßÔ­BSA (400mg/kg)£¬¸ôÌì¹à裬һÁ¬6ÖÜ £»Æ¤ÏÂ×¢Éä±ÍÂéÓÍ(0.5ml)ºÍCCl4(0.1ml),1´Î£¯ÖÜ£¬Ò»Á¬9Öܲ¢ÍŽáÔËÓÃLPS£¨»®·ÖÓÚµÚ6¡¢8 ÖÜÒÔ0.05mgβ¾²Âö×¢É䣩¡£µÚ10ÖÜÄ©Õý·¨¶¯ÎȡѪ±ê±¾ºÍÉöÔà×öÏìÓ¦¼ì²é¡£

2.Ö¸±ê¼ì²â ²â¶¨ÑªÇåÇåÂѰס¢ÑªÇå×ÜÂѰס¢BUN¡¢Cr¡¢¹È±ûת°±Ã¸ºÍ¹È²Ýת°±Ã¸¡£ÁíÍ⣬ÿ¸ôÈýÖܼì²â1´Î24СʱÄòÂѰ׺ÍÄòͨÀý¡£ÉöÔಡÀíÇÐÆ¬¾ÙÐÐH&EºÍPASȾɫ£¬¼ÆÊýÉöСÇò¸öÊý²¢ÅÌËãÉöСÇòÏµÄ¤ÇøÕ¼Õû¸öÉöÔàëϸѪ¹Ü´ÔÃæ»ýµÄ°Ù·Ö±È£¬×îºó£¬¶ÔÉöÔà¾ÙÐÐIgAÃâÒßÓ«¹âÇ¿¶È·Ö¼¶¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.´óÊó¾ù·ºÆðÂѰ×Äò£¬ÆäÖÐ70£¥·ºÆðÈâÑÛѪÄò£¬30£¥·ºÆð¾µÏÂѪÄò£¬ÃâÒßÓ«ÏÊÃ÷ʾÉö×éÖ¯£®IgA Ç¿¶È(2Æß3+£©£¬¹â¾µPASȾɫÏÔʾÓÐÃÖÂþÐÔµÄÇáÖжÈÏµÄ¤ÇøÔöÉú£¬ÑªÇåÂѰ׽µµÍ£¬µ«×ª°±Ã¸Ë®Æ½ÎÞת±ä¡£ 2.ÔÚÔìÄ£ÒªÁìÖУ¬LPSÊÇÃâÒß×ô¼Á£¬¶¾ÐÔ½ÏÍâ

2.¶¾ËØÆÏÌÑÇò¾ú³¦¶¾ËØÈõ£¬²»Ò×¶Ô¶¯Îï»úÌåÔì³ÉË𺦡£½«¿Ú·þÃâÒßÔ­BSAµÄ¼ÁÁ¿Îª400mg/kg£¬¸ôÈÕ1´ÎÒÔ¼°CC14ÒÔ0.1ml¼Á×îÆ¤ÏÂ×¢É価¿ÉÄÜïÔÌ­¶Ô¸ÎÔàµÄË𺦡£Í¨¹ýÒÔÉϸÄÁ¼£¬Ä£×Ó×élgAÔÚÉöÔà×éÖ¯ÓнÏÇ¿³Á»ý£¬²Ù×÷ÆðÀ´¸üÀû±ãºÍÇå¾²£¬²»Ò×ÒýÆð¸¹Ç»Ñ¬È¾ºÍ¶¯ÎïéæÃü£¬²¢ÇÒÎÞÏÔןÎÔàË𺦡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

lgAÉö²¡ÊÇ×î³£¼ûµÄÔ­·¢ÐÔÉöСÇò¼²²¡£¬Ô¼Õ¼Ô­·¢ÐÔÉöСÇò¼²²¡µÄ1/3¡£½ÓÄɸ´ºÏ¸ÄÁ¼·¨ÔìÄ£ÊÇÏÖÔÚlgAÉö²¡ÖнÏΪ¿É¿¿Îȹ̡¢ÀÖ³ÉÂʸߣ¬ÇÒ²¡Àí¡¢ÁÙ´²Ö¸±ê¿¿½üÈËÀàIgAÉö²¡µÄ¶¯ÎïÄ£×Ó¡£ËüսʤÁ˿ڷþÃâÒßÔ´£«¸ÎÔàÇгý£«ÃâÒß×ô¼Á¸´ºÏÔìÄ£·¨¶¯ÎïéæÃüÂʸߣ¨Ô¼50%£©µÄÈõµã £»ÆÏÌÑÇò¾ú³¦¶¾ËØ£«¿Ú·þÃâÒßÔ´£«ÃâÒß×ô¼Á¸´ ºÏÔìÄ£·¨ÒòÆÏÌÑÇò¾ú³¦¶¾ËØÊÇÍâ¶¾ËØ£¬¶¾ÐÔ´ó£¬Ò×ÒýÆð»úÌåË𺦠£»¸¹Ç»×¢ÉäCC14Òý·¢µÄIgAÉö²¡Ä£ ÐÍ£¬ËäÈ»ÓиßÇ¿¶ÈµÄIgA³Á»ý£¬µ«¸ÎÔ๦ЧËðº¦ÑÏÖØ£¬³£°éÓиÎϸ°û»µËÀ¡¢±äÐԺͼÙСҶÌìÉú¡£ÓÿгÝÀදÎï¸´ÖÆµÄIgAÉö²¡Ä£×Ó£¬ÆäѪÇåIgAÌØÕ÷ÓëÈËÀà±£´æ½Ï´ó²î±ð£¬¹ÊÆÚÍû½¨Éè»ùÒò¹¤³ÌÄ£×ÓÀ´Õ½Ê¤Æäȱ·¦¡£

  

²Î¿¼ÎÄÏ×£º

1.ÌÀÓ±£¬Â¦Ì½Ææ£¬³É²ÊÁª£¬µÈʵÑéÐÔIgAÉö²¡Ä£×ÓµÄˢУ®ÖÐɽ´óѧѧ±¨£¨Ò½Ñ§¿ÆÑ§°æ£©£¬2006,27 (2): 184-187

2.Î⺺Àû£¬Ëïΰ£®°¢Èá±ÈÐǽ¨ÉèÉö²¡Ä£×ӵįÀ¼Û£®ÖйúÖÐÒ½¼±Ö¢£¬2010,19 (2):290-191

3.ÕÅÀö·Ò£¬»ÆÎÄÕþ£¬ÖìС馣¬µÈ£®°¢Ã¹ËØÉö²¡ÉöСÇòÓ²»¯¶¯ÎïÄ£×ÓµÄÑо¿. ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2005,6 (4):195-199

4.Õſ˷Ç£¬ÕÅÁÁ£¬ÎâÐÛ·É£¬µÈ£®´óÊó¿¹Thy1ϵĤÔöÉúÐÔÉöСÇòÉöÑ×Ä£×Ó·¢²¡»úÖÆÌ½ÌÖ£®ËÄ´¨´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬ 2004,35 (2): 188-190

5.³Â¹ãƽ£¬¹ù¹§ÒÀ£¬ÕÅԶ𣬵ȣ®´óÊóThy1¿¹ÑªÇåÖÆ±¸¼°ÏµÄ¤ÔöÉúÐÔÉöÑ×Ä£×ӵĽ¨É裮ÁÙ´²ÓëʵÑ鲡ÀíѧÔÓÖ¾£¬1996, 12 (3):241-243

6.»ÆÊ¤£¬ËïÁÖ£¬Ò¶Èθߣ¬µÈ£®Á½ÖÖϵĤÔöÖ³ÐÔÉöÑ×´óÊóÄ£×ӵĽ¨Éè½ÏÁ¿£®ÖйúʵÑ鶯Îïѧ±¨£¬2002, 10 (4): 236-238

7.Marquina R, Dfez MA,López-Hoyos M,el al. Inhibition of B cell death causes the development of an lgA nephropathy in(New Zealand white x C578L/6)F(l)-bel-2 transgenic mice. J lmmunol,2004,172(11):7177-7185

8.Zhang Z, Kundu GC, Yuan CJ, el al. Severe fibroneclin­deposit renal glomerular disease in mice lacking uteroglobin. Science, 1997,276(5317): 1408-1412

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿